PMID- 23032422
OWN - NLM
STAT- MEDLINE
DCOM- 20130603
LR  - 20151119
IS  - 1473-5571 (Electronic)
IS  - 0269-9370 (Linking)
VI  - 26
IP  - 18
DP  - 2012 Nov 28
TI  - The influence of HLA supertype on thymidine analogue associated with low 
      peripheral fat in HIV.
PG  - 2337-44
LID - 10.1097/QAD.0b013e32835ab213 [doi]
AB  - OBJECTIVES: To examine the relationship between human leukocyte antigen (HLA) 
      genotype and body composition changes induced by thymidine analogue nucleoside 
      reverse transcriptase inhibitor (NtRTI) use in HIV-positive individuals. DESIGN: 
      Data collected during the Simplification with Tenofovir-Emtricitabine (TDF-FTC) 
      or Abacavir-Lamivudine (ABC-3TC) (STEAL) study were analysed to examine the 
      potential association of HLA genotypes with changes in body composition in 
      treatment-experienced HIV-positive individuals. METHODS: Demographic, 
      HIV-related, body composition and HLA genotyping data from the STEAL study were 
      used in this analysis. The mean percentage peripheral fat at study baseline was 
      compared in participants with and without prior NtRTI use. Analyses were also 
      carried out for each HLA supertype strata, for five HLA genes, within the 
      thymidine-exposed group. These comparisons were made using Mann-Whitney rank-sum 
      tests. RESULTS: Participants with prior NtRTI use had a significantly lower 
      baseline mean peripheral fat percentage compared to those without NtRTI use (31.9 
      vs. 34.7%; P = 0.0045). However, participants carrying one or more of the three 
      particular HLA supertype alleles, A01, B08 and DQ2, showed no significant 
      difference in mean peripheral fat percentage at baseline by NtRTI use. Among 
      participants with prior NtRTI exposure, there were significant differences in 
      mean peripheral fat by HLA A01, B08 and DQ2 allele expression compared to those 
      without expression of these alleles (A01: 34.91% vs. no A01: 30.3%; P = 0.0087; 
      B08: 36.2% vs. no B08: 31.1%; P = 0.0317; DQ2: 35.16% vs. no DQ2: 30.06%; P = 
      0.0081). CONCLUSION: This analysis suggests that HIV-infected individuals 
      carrying HLA A01, B08 or DQ2 supertype alleles may be resistant to NtRTI-induced 
      peripheral fat loss.
FAU - Cordery, Damien V
AU  - Cordery DV
AD  - The Kirby Institute, University of New South Wales, Sydney, Australia. 
      dcordery@kirby.unsw.edu.au
FAU - Martin, Allison
AU  - Martin A
FAU - Amin, Janaki
AU  - Amin J
FAU - Kelleher, Anthony D
AU  - Kelleher AD
FAU - Emery, Sean
AU  - Emery S
FAU - Cooper, David A
AU  - Cooper DA
CN  - STEAL study group
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - AIDS
JT  - AIDS (London, England)
JID - 8710219
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Dideoxynucleosides)
RN  - 0 (Drug Combinations)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-A1 Antigen)
RN  - 0 (HLA-B8 Antigen)
RN  - 0 (HLA-DQ Antigens)
RN  - 0 (HLA-DQ2 antigen)
RN  - 0 (Organophosphonates)
RN  - 0 (abacavir, lamivudine drug combination)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 2T8Q726O95 (Lamivudine)
RN  - 99YXE507IL (Tenofovir)
RN  - G70B4ETF4S (Emtricitabine)
RN  - JAC85A2161 (Adenine)
RN  - VC2W18DGKR (Thymidine)
SB  - IM
MH  - Adenine/analogs & derivatives/pharmacology
MH  - Anti-HIV Agents/*pharmacology
MH  - Australia
MH  - Biomarkers/metabolism
MH  - Blood Glucose
MH  - *Body Fat Distribution
MH  - CD4 Lymphocyte Count
MH  - Deoxycytidine/analogs & derivatives/pharmacology
MH  - Dideoxynucleosides/pharmacology
MH  - Drug Combinations
MH  - Drug Resistance, Viral
MH  - Emtricitabine
MH  - Female
MH  - Genotype
MH  - HIV Infections/drug therapy/genetics/*metabolism
MH  - HIV-Associated Lipodystrophy Syndrome/drug therapy/genetics/*metabolism
MH  - HLA Antigens/drug effects/*metabolism
MH  - HLA-A1 Antigen/metabolism
MH  - HLA-B8 Antigen/metabolism
MH  - HLA-DQ Antigens/metabolism
MH  - Humans
MH  - Lamivudine/pharmacology
MH  - Linkage Disequilibrium
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Organophosphonates/pharmacology
MH  - Predictive Value of Tests
MH  - Randomized Controlled Trials as Topic
MH  - Tenofovir
MH  - Thymidine/analogs & derivatives/*metabolism
FIR - Cooper, David
IR  - Cooper D
FIR - Bloch, Mark
IR  - Bloch M
FIR - Carr, Andrew
IR  - Carr A
FIR - Baker, David
IR  - Baker D
FIR - Finlayson, Robert
IR  - Finlayson R
FIR - Hoy, Jennifer
IR  - Hoy J
FIR - Read, Tim
IR  - Read T
FIR - Doong, Nicholas
IR  - Doong N
FIR - Roth, Norman
IR  - Roth N
FIR - Anderson, Jonathan
IR  - Anderson J
FIR - Moore, Richard
IR  - Moore R
FIR - Chuah, John
IR  - Chuah J
FIR - Street, Alan
IR  - Street A
FIR - Shaw, David
IR  - Shaw D
FIR - Orth, David
IR  - Orth D
FIR - Kelly, Mark
IR  - Kelly M
FIR - Smith, David
IR  - Smith D
FIR - Nolan, David
IR  - Nolan D
FIR - Boyd, Mark
IR  - Boyd M
FIR - Gordon, David
IR  - Gordon D
FIR - Medland, Nicholas
IR  - Medland N
FIR - Tee, Ban Kiem
IR  - Tee BK
FIR - Dwyer, Dominic
IR  - Dwyer D
FIR - Dyer, John
IR  - Dyer J
FIR - Woolley, Ian
IR  - Woolley I
FIR - Giles, Michelle
IR  - Giles M
FIR - Davies, Stephen
IR  - Davies S
FIR - Dayan, Linda
IR  - Dayan L
FIR - Donohue, William
IR  - Donohue W
FIR - Russell, Darren
IR  - Russell D
FIR - Post, Jeffrey
IR  - Post J
FIR - Quin, John
IR  - Quin J
FIR - Smith, Don
IR  - Smith D
FIR - Allworth, Anthony
IR  - Allworth A
EDAT- 2012/10/04 06:00
MHDA- 2013/06/05 06:00
CRDT- 2012/10/04 06:00
PHST- 2012/10/04 06:00 [entrez]
PHST- 2012/10/04 06:00 [pubmed]
PHST- 2013/06/05 06:00 [medline]
AID - 10.1097/QAD.0b013e32835ab213 [doi]
PST - ppublish
SO  - AIDS. 2012 Nov 28;26(18):2337-44. doi: 10.1097/QAD.0b013e32835ab213.